Leap Therapeutics
Presença
Leap Therapeutics é uma empresa listada sob o símbolo LPTX (US).
Executivos
Veja o organograma con seus 16 executivos principais
Biografias mais buscadas da Leap Therapeutics
- Doug Onsi, President, Chief Executive Officer and Chief Financial ...
- William Li, Director
- Chris Mirabelli, Chairman of the Board
Criar um alerta
para seguir os movimentos de executivos da Leap Therapeutics.
Biotecnologia
Leap Therapeutics possui 2.289 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Lycia Therapeutics acaba de anunciar uma arrecadação de fundos de 107 milhões de dólares. (publicado em 15 de maio de 2024).
- Attovia Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 14 de maio de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado em 13 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Leap Therapeutics
- Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer | Leap Therapeutics, Inc.
- Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 | Leap Therapeutics, Inc.
- Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting | Leap Therapeutics, Inc.
- Leap Therapeutics Reports First Quarter 2022 Financial Results | Leap Therapeutics, Inc.
- Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results | Leap Therapeutics, Inc.
- Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference | Leap Therapeutics, Inc.
- Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients | Leap Therapeutics, Inc.
- Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference | Leap Therapeutics, Inc.
- Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares | Leap Therapeutics, Inc.
- Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants | Leap Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Leap Therapeutics
- Leap Therapeutics na Wikipedia, Google News e Yahoo Finance
- Leap Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Doug Onsi 
Ligue para a Leap Therapeutics em +1 617...
